These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 19896530)

  • 21. Dopamine, a co-regulatory component, bridges the central nervous system and the immune system.
    Li M; Zhou L; Sun X; Yang Y; Zhang C; Wang T; Fu F
    Biomed Pharmacother; 2022 Jan; 145():112458. PubMed ID: 34847478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.
    Carnicella S; Drui G; Boulet S; Carcenac C; Favier M; Duran T; Savasta M
    Transl Psychiatry; 2014 Jun; 4(6):e401. PubMed ID: 24937095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases.
    Levite M
    Acta Physiol (Oxf); 2016 Jan; 216(1):42-89. PubMed ID: 25728499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopaminergic Pathways in Obesity-Associated Inflammation.
    Leite F; Ribeiro L
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):93-113. PubMed ID: 31317376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions.
    Peacock L; Gerlach J
    Biol Psychiatry; 2001 Oct; 50(7):501-9. PubMed ID: 11600103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.
    Matt SM; Gaskill PJ
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):114-164. PubMed ID: 31077015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
    Xu D; Karain B; Brantley E; Shi WX
    J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
    Monti JM; Jantos H
    Prog Brain Res; 2008; 172():625-46. PubMed ID: 18772053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in dopamine receptor agonists for the treatment of Parkinson's disease.
    Stocchi F; Torti M; Fossati C
    Expert Opin Pharmacother; 2016 Oct; 17(14):1889-902. PubMed ID: 27561098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K; Gille G; Rausch WD
    Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.
    Hirose T; Kikuchi T
    J Med Invest; 2005 Nov; 52 Suppl():284-90. PubMed ID: 16366516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway.
    Zhao W; Huang Y; Liu Z; Cao BB; Peng YP; Qiu YH
    PLoS One; 2013; 8(6):e65860. PubMed ID: 23799052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Dopamine Signaling in Drug Addiction.
    Chen W; Nong Z; Li Y; Huang J; Chen C; Huang L
    Curr Top Med Chem; 2017; 17(21):2440-2455. PubMed ID: 28474551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basolateral amygdala modulation of the nucleus accumbens dopamine response to stress: role of the medial prefrontal cortex.
    Stevenson CW; Gratton A
    Eur J Neurosci; 2003 Mar; 17(6):1287-95. PubMed ID: 12670317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microglial responses to dopamine in a cell culture model of Parkinson's disease.
    Mastroeni D; Grover A; Leonard B; Joyce JN; Coleman PD; Kozik B; Bellinger DL; Rogers J
    Neurobiol Aging; 2009 Nov; 30(11):1805-17. PubMed ID: 18325635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.
    Fuxe K; Guidolin D; Agnati LF; Borroto-Escuela DO
    Expert Opin Ther Targets; 2015 Mar; 19(3):377-98. PubMed ID: 25486101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine acting at D1-like, D2-like and α1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex.
    Özkan M; Johnson NW; Sehirli US; Woodhall GL; Stanford IM
    PLoS One; 2017; 12(7):e0181633. PubMed ID: 28732063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.